Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urogenital Neoplasms 1Prostatic Neoplasms 1Prostatic Diseases 1

Interventions

Abiraterone Acetate 2vedolizumab 1tislelizumab 1onapristone 1olaparib 1abiraterone 1Pluvicto 1Neoadjuvant Therapy 1National Cancer Institute (U.S.) 1Lutetium-177 1Lutetium 1LDP-02 1Infliximab 1Immunoglobulin G 1Docetaxel 1Disulfides 1CT-P13 1BAY 86-7548 1Androgen Antagonists 1Adrenal Cortex Hormones 1Administration, Intravesical 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Urogenital Neoplasms × Lutetium × Clear all
NCT05413850 2026-05-14

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Blue Earth Therapeutics Ltd

Phase 1/2 Recruiting
82 enrolled
Genitourinary

Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡